南方医科大学:肠道菌群用于IBD诊断和疗效预测
创作:aluba 审核:aluba 2018年03月25日
  • 分析中国IBD患者及2个西方IBD人群的肠道菌群,不同人种患者的肠道菌群变化模式类似;
  • 基于肠道菌群开发出一套预测模型用于IBD诊断,克罗恩病及溃疡性结肠炎的预测准确率分别为87.5%及79.1%;
  • 放线菌门及变形菌门的增加及厚壁菌门的减少与IBD严重程度显著相关;
  • 对英夫利昔单抗治疗应答的患者治疗后肠道菌群多样性恢复,梭菌目相对丰度显著增加;
  • 结合钙网蛋白水平及克罗恩病活动指数,可高准确率地预测患者对英夫利昔单抗治疗的应答。
主编推荐语
aluba
南方医科大学陈烨和周宏伟团队主导的最新研究,基于肠道菌群开发诊断标志物,可用于不同人种的IBD诊断,结合肠道菌群及其它指标,可用于IBD患者对英夫利昔单抗治疗应答的预测。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
mSystems [IF:6.496]

Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction

肠道菌群作为IBD诊断及英夫利昔应答预测的跨种族通用生物标志物

10.1128/mSystems.00188-17

2018-01-30, Article

Abstract & Authors:展开

Abstract:收起
Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn's disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels ofand() and a relative decrease in the levels of() were strongly correlated with IBD severity (< 0.05). Additionally, restoration of gut microbiota diversity and a significant increase inrelative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn's disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD.In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.

First Authors:
Youlian Zhou,Zhenjiang Xu,Yan He,Yunsheng Yang,Le Liu,Qianyun Lin,Yuqiang Nie,Mingsong Li,Fachao Zhi,Side Liu,Amnon Amir,Antonio Gonzalez,Anupriya Tripathi,Minhu Chen,Gary D Wu,Rob Knight,Hongwei Zhou

Correspondence Authors:
Youlian Zhou,Zhenjiang Xu,Yan He,Yunsheng Yang,Le Liu,Qianyun Lin,Yuqiang Nie,Mingsong Li,Fachao Zhi,Side Liu,Amnon Amir,Antonio Gonzalez,Anupriya Tripathi,Minhu Chen,Gary D Wu,Rob Knight,Hongwei Zhou

All Authors:
Youlian Zhou,Zhenjiang Xu,Yan He,Yunsheng Yang,Le Liu,Qianyun Lin,Yuqiang Nie,Mingsong Li,Fachao Zhi,Side Liu,Amnon Amir,Antonio Gonzalez,Anupriya Tripathi,Minhu Chen,Gary D Wu,Rob Knight,Hongwei Zhou,Ye Chen

评论